NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to ...

In its upcoming report, TransMedics (TMDX) is predicted by Wall Street analysts to post quarterly earnings of $0.18 per share, reflecting an increase of 50% compared to the same period last year.

TransMedics is revolutionizing organ transplant therapy with its FDA-approved Organ Care System. See why I rate TMDX stock as ...

Van ECK Associates Corp grew its holdings in TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 102.3% in the fourth ...

NEW YORK, Feb. 22, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts ...

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

The complaint alleges that TransMedics made false and misleading statements, while failing to disclose crucial information. Specifically, the suit contends that TransMedics used kickbacks ...

TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ...

In truth, it appears that TransMedics fueled its growth by engaging in an anti-competitive scheme, including providing kickbacks to medical providers. The company further boosted growth by engaging in ...

SAN FRANCISCO, Feb. 21, 2025 /PRNewswire/ -- A class-action lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy ...